Skip to main content

We are committed to patients with hemophilia and the bleeding disorders community.

Ongoing focus

Icon: Ongoing focus Page: About

At Novo Nordisk, we believe that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way.

Product portfolio

Icon: Product portfolio

We aspire to be a respected leader in the health care industry, helping patients with treatments for a broad range of bleeding disorders.

Environmental awareness

Icon: Environmental awareness

We also strive to minimize the environmental impact of our activities. Our facilities in Denmark supply quality products in a socially responsible and environmentally sound way, using 100% renewable energy.

The Triple Bottom Line.

The Triple Bottom Line (TBL) is Novo Nordisk’s way of doing business. We believe that a healthy economy, environment, and society are fundamental to long-term business success. We are one of only four companies in the world who have incorporated our philosophy into our company bylaws.

Everything we do and every decision we make is informed by the three pillars of TBL:

Social impact.

Social responsibility is about caring for people. This applies to the people who depend on our products, as well as to our employees. We work to continuously integrate social, health, and safety considerations into our daily business.


Environmental responsibility.

Environmental soundness addresses our impact on the external environment – and we've taken a concerted approach to ensure that our efforts to be green pay off.

The campus of our LEED Silver certified U.S. Headquarters demonstrates our approach to being responsible stewards of our environment, driven by the company’s commitment to help people live healthy lives, and consistent with Novo Nordisk's TBL business model.

Our campus utilized recycled and locally-sourced materials, and is fully powered by renewable energy from wind, solar, and hydro sources—a feature that is expected to lead to a 30 percent reduction in energy costs.


Financial performance.

Economic viability is about managing the business in a way that secures growth and value creation, and delivers competitive performance in these areas. Investing in our employees contributes to our award-winning workplace and supports our goal of delivering innovative achievements.

As of August 2017, Novo Nordisk Inc. has been ranked in Fortune Magazine's Best Places to Work listing every year since 2009. Most recently, Novo Nordisk was presented with the New Good Neighbor Award by the New Jersey Business & Industry Association. This award was based on a variety of factors, including economic benefit/job creation, architectural merit, and community involvement.

Novo Nordisk is also committed to investing in Research and Development. In 2016, 13% of sales went towards funding R&D projects across the organization.

Selected Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events

Indications and Usage

NovoSeven® RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for:

  • Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
  • Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia

Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events
  • Hypersensitivity reactions, including anaphylaxis, can occur with NovoSeven® RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur
  • Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed
  • Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis

Adverse Reactions

  • The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia

Drug Interactions

  • Thrombosis may occur if NovoSeven® RT is administered concomitantly with Coagulation Factor XIII

Please click here for Prescribing Information